Swartz T A, Handsher R
Department of Epidemiology and Preventive Medicine, Sackler Faculty of Medicine, Tel Aviv University, Israel.
Public Health Rev. 1993;21(1-2):99-106.
Following the introduction of a combined EIPV and OPV schedule in 1990, no more cases of paralytic poliomyelitis were diagnosed and no wild poliovirus strain was isolated in the sewage. 100% seropositivity and high geometric mean titers (GMTs) to the three types of poliovirus vaccine strains and to the type 1 poliovirus 1988 epidemic strain were observed at the completion of the immunization schedule and one year later. The study of the immune profile of various age groups vaccinated with either EIPV or OPV had shown that the immunity to the epidemic poliovirus strain was less satisfactory, in terms of percent of seropositivity and GMTs, than to the poliovirus vaccine strains. In individuals previously immunized with either EIPV or OPV a high and quick immune response to both the 1988 epidemic and vaccine strains was observed after a booster dose of OPV. Follow-up to four years after the booster pointed to some decrease in the extent and intensity of the seropositivity to the 1988 epidemic strain as compared to the immune profile to the poliovirus vaccine strains. Maintaining Israel in the phase of polio elimination requires: > 95% national coverage, homogenously distributed; maintaining high immune profile to the three poliovirus types, including a satisfactory immune level to the 1988 epidemic strain in all the age groups at risk of polio; early detection of the introduction of wild poliovirus into the environment and of the occurrence of foci of indigenous activity; reducing the risk of exposure to massive infectious doses.(ABSTRACT TRUNCATED AT 250 WORDS)
1990年采用联合的灭活脊髓灰质炎疫苗(EIPV)和口服脊髓灰质炎疫苗(OPV)免疫程序后,未再诊断出麻痹性脊髓灰质炎病例,且在污水中未分离出野生脊髓灰质炎病毒株。在免疫程序完成时及一年后,观察到对三种脊髓灰质炎疫苗株及1988年脊髓灰质炎1型流行株的血清阳性率达100%,且几何平均滴度(GMT)较高。对接种EIPV或OPV的不同年龄组免疫情况的研究表明,就血清阳性率百分比和GMT而言,对流行脊髓灰质炎病毒株的免疫力不如对脊髓灰质炎疫苗株的免疫力。在先前接种过EIPV或OPV的个体中,在接种一剂OPV加强针后,观察到对1988年流行株和疫苗株均有高而快速的免疫反应。加强针后四年的随访显示,与对脊髓灰质炎疫苗株的免疫情况相比,对1988年流行株的血清阳性率在范围和强度上有所下降。要使以色列维持在脊髓灰质炎消除阶段,需要:全国覆盖率>95%,且分布均匀;维持对三种脊髓灰质炎病毒型别的高免疫水平,包括在所有有脊髓灰质炎风险的年龄组中对1988年流行株有令人满意的免疫水平;尽早发现野生脊髓灰质炎病毒传入环境及本土活动疫点的出现;降低接触大量感染剂量的风险。(摘要截选至250字)